Composition: Each tablet contains:
Dried aluminium hydroxide gel . . . . . . . . . . . . .522,88 mg
(As Aluminium hydroxide. . . . . . . . . . . . . . . . . . . 400 mg)
Magnesium hydroxide. . . . . . . . . . . . . . . . . . . . . .400 mg
HD plastic bottle containing 50 or 100 chewable tablets in a carton box.
50 blisters of 10 chewable tablets in a carton box.
The symptomatic relief of gastric hyperacidity (heartburn, acid reflux, flatulence, dyspepsia due to increased acid).
Increased gastric acid due to gastric and duodenal ulcers.
Prevention and treatment of gastroduodenal ulcers or bleeding due to stress.
The symptomatic treatment of gastroesophageal reflux.
|Dosage and administration||
The usual dose for:
Hypersensitivity to aluminium hydroxide, magnesium hydroxide or any of the excipients.
|Warnings and precautions for use||
Caution should be exercised in patients with congestive heart failure, renal failure, edema, cirrhosis and low sodium diet and patients who have recently experienced GI bleeding.
|Recommendation for pregnancy and breastfeeding||
|Effects on ability to drive and use machines||
There have been no reports on the effects of this product on the ability to drive and use machines.
|Interactions, incompatibilities of medicine||
Magaltab containing aluminium hydroxide and magnesium hydroxide should not be taken simultaneously with medicines such as tetracycline, digoxin, indomethacin, iron salts, isoniazid, allopurinol, benzodiazepine, corticosteroid, penicillamine, phenothiazine, ranitidine, ketoconazole, itraconazole as it may reduce the absorption of these drugs.
|Undesirable effects (ADRs)||
At the recommended dose, side effects are uncommon (≥ 1/1, 000 to < 1/100).
|Overdose and management||
Information about overdose has not been reported.
Gastric-peptic disease results from an imbalance between protective factors, such as gastric mucosal barrier, bicarbonate secretion, and prostaglandin secretion, and aggressive gastric factors such as hydrochloric acid, pepsin, and Helicobacter pylori. Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.
The absorption of aluminium hydroxide and magnesium hydroxide from antacids is negligible, aluminium hydroxide is slowly converted to aluminium chloride in the stomach. Some absorption of soluble aluminium salts occurs in the gastro-intestinal tract with urinary excretion. Therefore, patients with renal impairment have high risk of aluminium accumulation (especially in the bone and central nervous system) and aluminium toxicity. Absorbed aluminium will bind to serum proteins (eg, albumin, transferrin) and thus it is difficult to remove aluminium by dialysis.
|Storage conditions, shelf-life, quality specification of the medicine||
Storage conditions: Protect from humidity and light, below 30 degrees C.